Literature DB >> 10756416

Myoclonus associated with the use of gabapentin.

J Asconapé1, A Diedrich, J DellaBadia.   

Abstract

PURPOSE: To report on the occurrence of myoclonus in patients receiving gabapentin (GBP) for the treatment of epilepsy.
METHODS: Clinic charts of 104 consecutive patients started on GBP were reviewed. All patients were treated by the same physician, and most were specifically asked about the presence of myoclonus.
RESULTS: We found 13 cases of myoclonus. All patients had refractory epilepsy and were taking other antiepileptic drugs (AEDs). Six patients had a severe chronic static encephalopathy; five patients had no medical diagnosis other than seizures. Ten patients developed multifocal myoclonus. Three patients developed focal myoclonus, contralateral to their epileptic focus. Two patients had an exacerbation of preexistent myoclonus. An EEG performed during myoclonus on three patients showed no correlate. The myoclonus tended to persist as long as GBP was maintained, whereas discontinuance of GBP resulted in rapid cessation of the myoclonus. In all cases the myoclonus was subtle and did not significantly interfere with daily activities.
CONCLUSIONS: GBP-associated myoclonus appears to be relatively frequent. It is usually mild and can easily be overlooked. Discontinuation of therapy is not necessary in most cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10756416     DOI: 10.1111/j.1528-1157.2000.tb00192.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

1.  Gabapentin-induced severe myoclonus in a patient with impaired renal function.

Authors:  Martin Holtkamp; Annett Halle; Hartmut Meierkord; Florian Masuhr
Journal:  J Neurol       Date:  2005-08-25       Impact factor: 4.849

Review 2.  Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 3.  Safety and tolerability of antiepileptic drug treatment in children with epilepsy.

Authors:  Renzo Guerrini; Gaetano Zaccara; Giancarlo la Marca; Anna Rosati
Journal:  Drug Saf       Date:  2012-07-01       Impact factor: 5.606

Review 4.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 5.  Antiseizure Drugs and Movement Disorders.

Authors:  Michel Sáenz-Farret; Marina A J Tijssen; Dawn Eliashiv; Robert S Fisher; Kapil Sethi; Alfonso Fasano
Journal:  CNS Drugs       Date:  2022-07-21       Impact factor: 6.497

Review 6.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Myoclonus induced by the use of gabapentin.

Authors:  Keun-Tae Cho; Seung-Koan Hong
Journal:  J Korean Neurosurg Soc       Date:  2008-05-20

8.  Gabapentin: An update of its pharmacological properties and therapeutic use in epilepsy.

Authors:  Azim Honarmand; Mohammadreza Safavi; Mohammad Zare
Journal:  J Res Med Sci       Date:  2011-08       Impact factor: 1.852

9.  Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy.

Authors:  A K Guddati; Z Zafar; J T Cheng; S Mohan
Journal:  Indian J Nephrol       Date:  2012-01

10.  Myoclonus in renal failure: Two cases of gabapentin toxicity.

Authors:  Kenneth R Kaufman; Amay Parikh; Lili Chan; Mary Bridgeman; Milisha Shah
Journal:  Epilepsy Behav Case Rep       Date:  2013-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.